References
- Toyn JH, Ahlijanian MK. Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β. Alheimer’s Res Ther 2014;6(2):14
- Albright CF, Dockens RC, Meredith JE, et al. Pharmacodynamics of selective inhibition of γ-secretase by avagacestat. J Pharmacol Exp Ther 2013;344:686-95
- May PC, Dean RA, Lowe SL, et al. Robust central reduction of amyloid- β in humans with an orally available non-peptidic, β-secretase inhibitor. J Neurosci 2011;31:16507-16
- Bateman RJ, Siemers ER, Mawuenyega KG, et al. A γ-secretase inhibitor decreases amyloid-β production in the central nervous system. Ann Neurol 2009;66:48-54
- Doody RS, Raman R, Farlow M, et al. A phase III trial of semagacestat for treatment of Alzheimer’s disease. New Engl J Med 2013;369:341-50
- Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009;302:2557-64
- Yan R, Vassar R. Targeting the β secretase BACE1 for Alzheimer’s disease therapy. Lancet 2014;13:319-29
- Svedružić Ž, Popović K, Šengula-Jengić V. Modulators of γ -secretase activity can facilitate the toxic side-effects and pathogenesis of Alzheimer’s disease. PLoS One 2013;8:e50759
- De Strooper B. Lessons from a failed γ-secretase Alzheimer trial. Cell 2014;159:721-6
- Mitani Y, Yarimizu J, Saita K, et al. Differential effects between γ -secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci 2012;32:2037-50
- Yu Y, Logovinsky V, Schuck E, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ -secretase modulator, E2212, in healthy human subjects. J Clin Pharmacol 2014;54:528-36
- Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomized, placebo-controlled trial. Lancet Neurol 2008;7(9):779-86
- Imagine trial of PBT2. Available from: www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=343427
- Salloway S, Sperling R, Keren R, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 2011;77:1253-62
- Aisen PS, Saumier D, Briand R, et al. A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006;67:1757-63
- Saumier D, Duong A, Haine D, et al. Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer’s disease: ADAS-cog subscale results from the Alphase study. J Nutrition Health Aging 2009;13:808-12
- Aisen PS, Gauthier S, Ferris SH, et al. Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-center study (the Alphase study). Arch Med Sci 2011;7:102-11
- Salloway S, Sperling R, Fox NC, et al. Two phase III trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370:322-33
- Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370:311-21
- Vellas B, Carrillo MC, Sampaio C, et al. Designing drug trials for Alzheimer’s disease: what have we learned from the release of phase III antibody trials: A report from the EU/US/CTAD task force. Alzheimers Dement 2013;9:438-44